---
title: Comparison of Topical Minoxidil 5% in Ethanol Plus Propylene Glycol Versus Minoxidil 5% in Ethanol Alone in Treatment of Women With Female Pattern Hair Loss
nct_id: NCT04090801
overall_status: COMPLETED
phase: PHASE4
sponsor: Sohag University
study_type: INTERVENTIONAL
primary_condition: Female Pattern Hair Loss
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04090801.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04090801"
ct_last_update_post_date: 2019-09-26
last_seen_at: "2026-05-12T07:15:42.813Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Comparison of Topical Minoxidil 5% in Ethanol Plus Propylene Glycol Versus Minoxidil 5% in Ethanol Alone in Treatment of Women With Female Pattern Hair Loss

**Official Title:** Minoxidil in Treatment of Androgenetic Alopecia

**NCT ID:** [NCT04090801](https://clinicaltrials.gov/study/NCT04090801)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** Sohag University
- **Conditions:** Female Pattern Hair Loss
- **Start Date:** 2015-05-30
- **Completion Date:** 2017-01-23
- **CT.gov Last Update:** 2019-09-26

## Brief Summary

The study will be included 60 women with FPHL. The diagnosis of FPHL will be established by clinical (Ludwig classification) and trichoscopic evaluation of frontal and occipital regions of the scalp.

## Detailed Description

Enrolled women will be randomly assigned into 3 treatment groups: group A will apply topical minoxidil 5% in 90% ethanol and 5% propylene glycol, group B will apply topical minoxidil 5% in pure ethanol alone and group C will apply pure ethanol (placebo) twice daily.

The treatment will be continued for six months with regular visits at 3 months intervals.

The medications will be provided in bottles which were identical in shape and color, and were coded by a third party.

Both patients and investigator will be blinded to the medication. Disclosure of the codes will be done, by a third party, at the end of the study.

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 60 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* FPHL

Exclusion Criteria:

* No
```

## Arms

- **Topical minoxidil 5% in 90% ethanol and 5% propylene glycol** (ACTIVE_COMPARATOR) — Group A applied topical minoxidil 5% in 90% ethanol and 5% propylene glycol
- **Topical minoxidil 5% in pure ethanol alone** (ACTIVE_COMPARATOR) — Group B applied topical minoxidil 5% in pure ethanol alone
- **Placebo** (PLACEBO_COMPARATOR) — Group C applied pure ethanol (placebo)

## Interventions

- **Topical minoxidil 5% in 90% ethanol and 5% propylene glycol** (DRUG)
- **Topical minoxidil 5% in pure ethanol alone** (DRUG) — The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
- **Placebo (Ethanol)** (OTHER) — The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.

## Primary Outcomes

- **Ludwig scale grading system** _(time frame: 0-6 months)_ — The 3 grades will be defined. Grade 1, (Thinning of hair is seen mainly over the anterior part of the crown with minimal widening of the parting width). Grade 2, (Thinning of the crown becomes more evident because of an increase in the number of thin and short hairs). Grade 3, (The crown becomes almost total bald, but the frontal hair line is still maintained).
- **Trichoscopic examination of the hairs at frontal and occipital regions of the scalp.** _(time frame: 0-6 months)_ — It will be evaluated signs of hair changes such as hair diameter diversity.

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04090801.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04090801*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*